These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11920187)

  • 1. Cyclin D1 expression in patients with multiple myeloma.
    Troussard X; Avet-Loiseau H; Macro M; Mellerin MP; Malet M; Roussel M; Sola B
    Hematol J; 2000; 1(3):181-5. PubMed ID: 11920187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections.
    Specht K; Kremer M; Müller U; Dirnhofer S; Rosemann M; Höfler H; Quintanilla-Martinez L; Fend F
    Clin Cancer Res; 2002 Sep; 8(9):2902-11. PubMed ID: 12231535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation.
    Yufu Y; Goto T; Choi I; Uike N; Kozuru M; Ohshima K; Taniguchi T; Motokura T; Yatabe Y; Nakamura S
    Cancer; 1999 Apr; 85(8):1750-7. PubMed ID: 10223569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).
    Pruneri G; Fabris S; Baldini L; Carboni N; Zagano S; Colombi MA; Ciceri G; Lombardi L; Rocchi M; Buffa R; Maiolo AT; Neri A
    Am J Pathol; 2000 May; 156(5):1505-13. PubMed ID: 10793062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels.
    Specht K; Haralambieva E; Bink K; Kremer M; Mandl-Weber S; Koch I; Tomer R; Hofler H; Schuuring E; Kluin PM; Fend F; Quintanilla-Martinez L
    Blood; 2004 Aug; 104(4):1120-6. PubMed ID: 15090460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).
    Janssen JW; Vaandrager JW; Heuser T; Jauch A; Kluin PM; Geelen E; Bergsagel PL; Kuehl WM; Drexler HG; Otsuki T; Bartram CR; Schuuring E
    Blood; 2000 Apr; 95(8):2691-8. PubMed ID: 10753852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAX5-positive plasma cell myeloma with t(9;14;11)(p13;q32;q13), a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32).
    Sato K; Sakai H; Kato M; Nishio Y; Tsuruoka Y; Uemura Y; Yokoi S; Saito T; Matsunawa M; Suzuki Y; Isobe Y; Inoue Y; Takahashi M; Miura I
    Int J Hematol; 2015 Jun; 101(6):608-11. PubMed ID: 25633778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1/PRAD1/BCL-1 alternative transcript [B] protein product in B-lymphoid malignancies with t(11;14)(q13;q32) translocation.
    Hosokawa Y; Joh T; Maeda Y; Arnold A; Seto M
    Int J Cancer; 1999 May; 81(4):616-9. PubMed ID: 10225453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin D1.
    Yata K; Sadahira Y; Otsuki T; Sakaguchi H; Isozaki Y; Uno M; Kurebayashi J; Fujii T; Eda S; Ueki A; Yawata Y; Yamada O; Sugihara T
    Br J Haematol; 2001 Sep; 114(3):591-9. PubMed ID: 11552984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.
    Hoyer JD; Hanson CA; Fonseca R; Greipp PR; Dewald GW; Kurtin PJ
    Am J Clin Pathol; 2000 Jun; 113(6):831-7. PubMed ID: 10874884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
    Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
    Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32).
    Kobayashi H; Saito H; Kitano K; Kiyosawa K; Gaun S; Aoki K; Narita A; Watanabe M; Uchimaru K; Motokura T
    Acta Haematol; 1995; 94(4):199-203. PubMed ID: 8610478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene.
    Vaandrager JW; Kluin P; Schuuring E
    Blood; 1997 Jan; 89(1):349-50. PubMed ID: 8978314
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignancies.
    Elnenaei MO; Jadayel DM; Matutes E; Morilla R; Owusu-Ankomah K; Atkinson S; Titley I; Mandala EM; Catovsky D
    Leuk Res; 2001 Feb; 25(2):115-23. PubMed ID: 11166826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin D1 positive multiple myeloma: predominance of the short, 3'UTR-deficient transcript is associated with high cyclin D1 mRNA levels in cases with t(11;14) translocation, but does not correlate with proliferation rate or genomic deletions.
    Slotta-Huspenina J; Koch I; Richter M; Bink K; Kremer M; Specht K; Krugmann J; Quintanilla-Martinez L; Fend F
    Leuk Res; 2008 Jan; 32(1):79-88. PubMed ID: 17629555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myelogenous leukemia with acquired t(11;14)(q13;q32) CCND1-IGH: A case report and literature review.
    Manda-Mapalo MT; Khalili P; Quintana D; Rabinowitz I; Zhang QY
    Cancer Genet; 2016 Oct; 209(10):481-485. PubMed ID: 27810077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
    Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
    Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy.
    Wilson CS; Butch AW; Lai R; Medeiros LJ; Sawyer JR; Barlogie B; McCourty A; Kelly K; Brynes RK
    Br J Haematol; 2001 Mar; 112(3):776-82. PubMed ID: 11260083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
    Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
    Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
    Fonseca R; Blood EA; Oken MM; Kyle RA; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Hoyer JD; Harrington D; Kay NE; Van Ness B; Greipp PR
    Blood; 2002 May; 99(10):3735-41. PubMed ID: 11986230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.